Computational analysis of Amyloid Beta aggregation inhibitors in combating Alzheimer's Disease.
Alzheimer's disease is the current leading form of dementia, constituting 60%-80% of cases of dementia. Alzheimer's disease is a primarily late onset disease which worsens over time. This increasing severity is a result of aggregation of amyloid b peptides resulting in the formation of plaques in the brain. A potential method of treatment for Alzheimer's consists of prevention and destabilization of amyloid b fibrils using biflavanoid molecules. Molecular Dynamics (MD), a computer-based method for simulating time-course molecular interactions based on Newtonian physics, can be used to simulate amyloid b peptides under biological conditions in the presence of the biflavanoid inhibitors in order to characterize key protein-drug interactions. Two potential AD drugs, Sciadopitysin and Sequoiaflavon, were modeled using MD and the interactions between the drugs and the amyloid b peptides were observed.
Keywords: Alzheimer's Disease, Computational Chemistry, Amyloid Beta
Topic(s):Chemistry
Presentation Type: Oral Paper
Session: 203-4
Location: MG 1096
Time: 10:15